Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 31Lymphoid 29Plasma cell 17Myeloid 14Sarcoma 11CNS 8Genitourinary 5Other solid neoplasm 4Breast 4Gynecologic 3Gastrointestinal 3Dermatologic 3Classical hematology 3Thoracic 1Other 1NET 1Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Granulocyte Colony-Stimulating Factor × Thoracic × Clear all
NCT00862134 2013-01-10

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Proacta, Incorporated

Phase 2 Terminated
42 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡